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Oxylipins play important roles in various biological processes and are considered as mediators of inflammation for a wide range of
diseases such as rheumatoid arthritis (RA).The purpose of this research was to study differences in oxylipin levels between a widely
used collagen induced arthritis (CIA)micemodel and healthy control (Ctrl) mice. DBA/1J male mice (age: 6-7 weeks) were selected
and randomly divided into two groups, namely, a CIA and a Ctrl group.The CIAmice were injected intraperitoneally (i.p.) with the
joint cartilage component collagen type II (CII) and an adjuvant injection of lipopolysaccharide (LPS). Oxylipin metabolites were
extracted from plasma for each individual sample using solid phase extraction (SPE) and were detected with high performance
liquid chromatography/tandem mass spectrometry (HPLC-ESI-MS/MS), using dynamic multiple reaction monitoring (dMRM).
Both univariate and multivariate statistical analyses were applied. The results in univariate Student’s t-test revealed 10 significantly
up- or downregulated oxylipins in CIA mice, which were supplemented by another 6 additional oxylipins, contributing to group
clustering upon multivariate analysis. The dysregulation of these oxylipins revealed the presence of ROS-generated oxylipins and
an increase of inflammation in CIA mice. The results also suggested that the collagen induced arthritis might associate with
dysregulation of apoptosis, possibly inhibited by activated NF-𝜅B because of insufficient PPAR-𝛾 ligands.
1. Introduction
Rheumatoid arthritis (RA) is a chronic, destructive autoim-
mune disease which involves primarily the joints in the
extremities.The disease is characterized by the destruction of
the cartilage in the joints and inflammation of the synovium.
This local immune response is characterized by both cell-
mediated and humoral immune factors. CD4+ T cells and
activated B cells are present in the synovium together with
cytokines such as interleukins (e.g., IL-1 and IL-6), tumor
necrosis factor (TNF𝛼), and interferon gamma (IF-𝛾) [1–3].
Recent studies have shown an important role of fibroblasts-
like synovial cells in the pathophysiology of RA [4–6]. Upon
proinflammatory stimuli and in combination with genetic
and epigenetic/environmental factors, these cells, normally
responsible for proper composition of the synovial fluid and
extracellular matrix, transform into an aggressive phenotype.
This phenotype is characterized by a reduced ability to
undergo apoptosis [7–12], the production of extracellular
enzymes like collagenase and metalloproteases responsible
for the destruction of the joints [13, 14], and the secretion
of (pro-/anti-) inflammatory cytokines, chemokines, proan-
giogenic factors, and oxylipins [15–17]. Due to local hypoxia,
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Although the role of cytokine/chemokine triggered signal
transduction pathways such as MAP kinase and nuclear
factor-kappa B (NF-𝜅B) in the pathophysiology of RA has
been subject of extensive research, the role of oxylipins is
less well understood. Oxylipins are bioactive lipid mediators
synthesized from omega-6 polyunsaturated fatty acid such
as arachidonic acid (AA), linoleic acid (LA), and dihomo-
gamma-linolenic acid (DGLA) and omega-3 polyunsaturated
fatty acid like eicosapentenoic acid (EPA), docosahexanoic
acid (DHA), and alpha-linolenic acid (ALA) upon libera-
tion from membrane bound phospholipids by activation of
phospholipase A2 and subsequent oxidation by cyclooxy-
genase (COX), lipoxygenase (LOX), and cytochrome P450
epoxygenase (CYP450) systems [22]. This leads to the for-
mation of, over at least hundred, bioactive oxylipins such
as prostaglandins (PG), leukotrienes (LT), thromboxanes
(TBX), hydroxyeicosatetraenoic acids (HETEs), and epoxye-
icosatrienoic acids (EpETrEs). They can act on both local
and distant targets by secretion into the circulation sys-
tem of body. AA is the substrate of proinflammatory lipid
mediators while EPA and DHA derived lipid mediators are
anti-inflammatory such as resolvins and protectins playing
a role in the resolution of inflammation [23]. Nonenzy-
matic oxidation of polyunsaturated fatty acids produces the
closely related bioactive lipids mediators like, for example,
isoprostanes, HETEs, and HDoHEs, indicators of oxidative
stress [24–29]. Therefore, investigation of the changes of
oxylipins in RA animalmodels will certainly contribute to the
understanding of biochemical events in RA research.
Metabolomics is an important and rapidly emerging
field of technology enabling the comprehensive analysis
of a large number of metabolites associated with disease
phenotypes.We have applied ametabolomics approach using
a LC-MS based platform combined with elaborate statistical
methods to analyze oxylipins in a validated model of RA
that is collagen induced arthritis in mice. Our results point
to a diminished anti-inflammatory response and increased
oxidative stress in the RA induced situation.
2. Materials and Method
2.1. Chemicals. Methanol (MeOH), acetonitrile (ACN), iso-
propanol (IPA), ethyl-acetate (EtOAC), and purified water
were purchased from Biosolve (Netherlands). All reagents
used during the HPLC-MS/MS experiments were ultra-
performance liquid chromatography grade (UPLC). Acetic
acid was purchased from Sigma-Aldrich (St. Louis, Mo).
Standards were purchased from Cayman (Netherlands).
2.2. Animal Studies. DBA/1J male mice (6-7 weeks; Charles
River Laboratories) were used in this study. Twenty mice
were randomly divided in two groups (10 in CIA group,
10 in Ctrl group as healthy control). In the CIA group,
immunization with collagen type II will provoke chronic
polyarthritis by the induced autoimmune response. Each
mousewas intraperitoneally induced (i.p.) with joint cartilage
component collagen type II (CII; 100𝜇g diluted with a 100 𝜇L
volume 0.005Macetic acid)whichwas extracted frombovine
nasal cartilage (Funakoshi Co., Tokyo, Japan) at day 0 (𝑇 = 0).
Thereafter, the CII injection was repeated i.p. on days 14, 28,
42, and 56. In the Ctrl mice, 100 𝜇L of 0.005M acetic acid
alone was administered i.p. on the same days (0, 14, 28, 42,
and 56).
Next, to all experimentalmice, 5mgof lipopolysaccharide
from E. coli 011:B4 (Chondrex, Redmond, USA) dissolved in
100 𝜇L phosphate buffered saline (PBS) was given i.p. imme-
diately after each injection of CII. In the Ctrl group, 100 𝜇L
PBS was similarly administered as a control. This protocol
for arthritis induction is well established and extensively
described [30]. All animals weremaintained in a temperature
and light controlled environment with free access to standard
rodent chow and water. From day 71 to day 75, blood was
taken from each animal of both groups (CIA mice (CIA1)
died when sampling, leaving 9 animal blood samples in
the CIA group) and collected in precooled tubes containing
EDTA (ethylenediaminetetraacetic acid) as coagulant (BD
Vacutainer, Plymouth, UK). After centrifugation at 3000 g for
10minutes, the EDTA-plasmawas collected and aliquots were
stored at −80∘C until further processing.
2.3. Ethics Statement. This study was carried out in strict
accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health. The experiments were performed with
the approval of the Tohoku Institute of Technology Research
Ethics Committee, Sendai, Japan (approval date 18 January
2009).
2.4. Oxylipin HPLC-MS/MS Analysis on Study Mouse Sam-
ples. The details of extraction and analysis of oxylipins
species were adapted for the analysis of mouse plasma
from a previously described oxylipin profiling method [31].
Antioxidant mixture (5 𝜇L) (0.4mg/mL BHT and 0.4mg/mL
EDTA mixed with volume ratio 1 : 1) and a mixture of
internal-standard mixtures (ISTDs) (5𝜇L, 1000 nM) were
added into each 50 𝜇L aliquot ofmouse plasma. Subsequently
the samples were loaded on the activated SPE plates (Oasis-
HLB 96-well plates, 60mg, 30 𝜇m) and eluted using ethyl
acetate (1.5mL). The dried eluate was redissolved in 50𝜇L
acetonitrile/methanol (50 : 50 v/v) and 5 𝜇L was analyzed by
HPLC (Agilent 1290, San Jose, CA, USA) on an Ascentis
Express column (2.1 × 150mm, particle size of 2.7 𝜇m)
coupled to electrospray ionization on a triple quadrupole
mass spectrometer (Agilent 6490, San Jose, CA, USA). Per-
formance characteristics for the adapted method including
recovery, linearity (𝑅2), linear dynamic range, and sensitivity
(LOD/LOQ) were evaluated in a separate validation exper-
iment and the results were comparable to those published
before for human plasma by Strassburg et al. [31]. The data
is included in the Supplementary Material (Table S1, Figure
S1, available online at http://dx.doi.org/10.1155/2015/543541).
2.5. Data Processing and Statistical Analysis. Peak areas were
exported from Mass Hunter software (Agilent Technologies,
version B.05.01) and ratios to internal standards were com-
puted (target compounds/ISTDs). Subsequently, an in-house
developedQC tool [32, 33] was used to correct for instrument
drift and batch effects. The reliability of the measurements
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was assessed by calculating the reproducibility of each
metabolite in a QC pool which was measured after every
10 samples. Oxylipins which met the criteria RSD-QC lower
than 35%were included in the final list for the further statisti-
cal analysis. Data were log transformed (Glog) and scaled by
the standard deviation (autoscaling) in order to get a normal
distribution [34, 35]. Univariate analysis (two-tailed unpaired
Student’s 𝑡-test) was employed to evaluate significant differ-
ences between groups for eachmetabolite (determined by𝑝 <
0.05). Principal component analysis (PCA) and partial least
square discriminant analysis (PLSDA) were performed to
further investigate the discrimination oxylipins between the
two groups using tools provided in the metaboanalyst soft-
ware package (http://www.metaboanalyst.ca/) [36]. Cross-
validation was used in order to validate the performance
of the PLS-DA model [37]. A permutation test with 100
iterations was performed to estimate the null distribution,
by randomly permuting the class labels of the observations.
𝑝 values of each pair of comparison in the permutation test
were calculated to evaluate the null hypotheses. To select the
potential important metabolites which contribute to group
separation, Variable Importance in the Projection (VIP)
scores based on PLS-DA analysis were used. The higher the
VIP score of a metabolite is, the greater its contribution in
the group clustering will be. VIP scores higher than 0.8 are
considered as meaningful. Variables with VIP score higher
than or equal to 1 were considered as significant important
features [38, 39].
3. Results
In this study, the relative concentrations of a panel of
oxylipins were determined in control and CIA mice. When
evaluating the results from the LC-MS/MS analysis, lower
responses of ISTDs peak areas were found in two samples,
which lead to an extreme high peak area ratio compared
with other study samples. Therefore, these two outliers from
Ctrl group were excluded from statistical analysis. The list of
detected endogenous oxylipins in mice plasma assigned by
their precursors is given in Table 1 (details in supplementary
table).
3.1. Univariate and Multivariate Analysis Results. From the
QC corrected data, a total of 30 unique oxylipins out of
a target list of 110 oxylipins included in the metabolomics
platformmet the criteria RSD-QC<35%. In order to generally
visualize the variance of the samples, a principal components
analysis (PCA), as an unsupervised multivariate analysis
approach, was performed using these oxylipins. Figure 1
displays the PCA results in the form of a score plot. The first
two principal components accounted for 60.1% of the total
variance (PC1 35.6% and PC2 24.5%, resp.), which means the
model explains well the variance of the samples. The score
plot showed a natural distribution of samples between the
CIA group and Ctrl group (consisting of the symbols “△”
or “+” plots). All 8 samples (100%) of Ctrl group clustered in
PCA. Eight out of 9 mice (88.9%) of CIA group clustered as
well, while one sample in CIA group was misclassified and
















Figure 1: PCAplot of oxylipin data in studymice plasma. PCA score
plot of plasma oxylipin data from all study samples revealed general
clusters in CIA mice samples and Ctrl samples. The individual
samples weremarkedwith “△” or “+” to show the group (CIA versus
Ctrl) clustering.
there are some differences between the samples, which were
mainly a reflection of the CIA/Ctrl groups.
Determining the oxylipin species responsible for the dif-
ferences between the CIA and Ctrl group is key to unraveling
the biological role of this class of compounds in RA. Student’s
𝑡-test is one of the most widely used methods to determine
the statistical significance. In order to understand which of
the detected oxylipins showed significant differences between
the two groups, an unpaired Student’s 𝑡-test analysis was
evaluated in each individual metabolite. From the 𝑡-test, 10
out of the 30 detected oxylipins (percentage of 33.3%) showed
significant differences (𝑝 < 0.05), namely, 9,10-DiHOME, 9-
KODE, 12,13-DiHOME, 14-HDoHE, 13-HDoHE, 12S-HEPE,
9,12,13-TriHOME, 9,10,13-TriHOME, 9,10-EpOME, and 10-
HDoHE. In order to show the effect size and variance among
the samples, a comparison of individual metabolite levels
measured for CIA and control mice is displayed in Figure 2,
in the form of boxplots, with “∗” indicating statistical signif-
icance between groups. In the boxplot, lines extended from
the boxes (whiskers) showed the variabilities outside from the
upper and lower quartiles of the data.
Given that compounds which showed nonsignificant
changes from univariate approaches (such as 𝑡-tests) may
also contribute to group clustering and provide useful infor-
mation on biological interpretation, a PLS-DA model as a
supervised clustering method was further applied to get a
more focused view on the metabolites which contribute to
group clustering. A PLS-DA scores plot using two com-
ponents with total score of 43.5% (component 1 = 24.5%,
component 2 = 19%) gives a reasonable group separation
(figure in supplementary data). However, this model needs
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Table 1: List of oxylipins detected inmice plasma,measured bymultiple reactionmonitoring (precursor ions → product ions) in LC-MS/MS
analysis.
Compounds MS transitions (𝑚/𝑧) 𝑝 value VIP Regulation Pathway
LA
9,10-DiHOME 313.2 → 201.1 0.0002 1.86 ↓ CYP450
12,13-DiHOME 313.2 → 183.2 0.006 1.51 ↓ CYP450
9,10-EpOME 295.2 → 171.2 0.028 1.27 ↓ CYP450
12,13-EpOME 295.2 → 195.2 0.096 1.00 ↓ CYP450
9-KODE 293.2 → 185.2 0.003 1.61 ↓ 5-LOX
9,12,13-TriHOME 329.2 → 211.2 0.017 1.36 ↓ 5-LOX
9,10,13-TriHOME 329.2 → 171.1 0.026 1.29 ↓ 5-LOX
9-HODE 295.2 → 171.1 0.052 1.14 ↓ 5-LOX
13-KODE 293.2 → 113.1 0.082 1.04 ↓ 12/15-LOX
13-HODE 295.2 → 195.2 0.733 0.21 — 12/15-LOX
EPA
12-HEPE 317.2 → 179.1 0.016 1.37 ↑ 12/15-LOX
DHA
14-HdoHE 343.2 → 205.0 0.010 1.45 ↑ ROS
13-HdoHE 343.2 → 281.0 0.012 1.42 ↑ ROS
10-HdoHE 343.2 → 153.0 0.035 1.23 ↑ ROS
17-HdoHE 343.2 → 281.3 0.173 0.83 — 12/15 LOX




369.2→ 163.1 0.390 0.53 — COX
8-HETrE 321.3 → 303.0 0.469 0.45 — 12/15 LOX
AA
8-HETE 319.2 → 155.1 0.074 1.06 ↑ 12/15-LOX
12-HETE 319.2 → 179.2 0.116 0.95 ↑ 12/15 LOX
15-HETE 319.2 → 219.2 0.770 0.18 — 12/15-LOX
5-HETE 319.2 → 115.1 0.713 0.23 — 5-LOX
13,14-dihydro-PGF
2𝛼
355.2 → 275.3 0.112 0.96 ↑ COX
PGF2
𝛼
353.2 → 193.1 0.176 0.82 — COX
13,14-dihydro-15-keto-PGF
2𝛼
353.2→ 183.1 0.618 0.31 — COX
12S-HHTrE 279.2 → 179.2 0.733 0.21 — COX
TXB2 369.2 → 169.1 0.900 0.08 — COX
14,15-DiHETrE 337.2 → 207.2 0.662 0.27 — CYP450
9-HETE 319.2 → 167.1 0.408 0.51 — ROS
11-HETE 319.2 → 167.1 0.820 0.14247 — ROS
The oxylipins are grouped based on the original polyunsaturated fatty acid precursor: linoleic acid (LA), eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA), dihomo-𝛾-linolenic acid (DGLA), and arachidonic acid (AA). Their metabolic pathways include enzymatic pathways: cyclooxygenase (COX),
lipoxygenase (LOX), cytochrome P450 (P450), and nonenzymatic reactive oxygen species (ROS) pathway.The significance of changes between two groups was
illustrated by 𝑝 value from univariate test (Student’s 𝑡-test) and VIP score from multivariate test (PLS-DA). The important regulations in the CIA group were
marked with “↓” or “↑” selected based on VIP scores.
↓: downregulated in CIA group.
↑: upregulated in CIA group.
to be validated in order to prevent overfitting. Therefore,
cross-validation and permutation test was performed. The
predictive accuracy (0.88) accompanied with a goodness of
fit 𝑅2 (0.84) in cross-validation revealed a sound basis for
the PLS-DA model. The permutation tests with an average
of 4 misclassifications in 100 iterations (𝑝 = 0.04) showed
robustness of the model. Thus classification of groups based
on this approach can be considered as significant based on
both cross-validation and 100 permutation tests.
For this model, the Variable Importance in the Projection
(VIP) score was used to summarize the relative contribu-
tions of each individual metabolite to the group separation
in the PLS-DA. The VIP score shows 14 variables which
contributed to the group clustering (VIP > 1), including 5
upregulated oxylipins (14-HDoHE, 13-HDoHE, 12S-HEPE,
10-HDoHE, and 8-HETE) and 9 downregulated oxylipins
(9,10-DiHOME, 9-KODE, 12,13-DiHOME, 9,12,13-TriHOME,
9,10,13-TriHOME, 9,10-EpOME, 9-HODE, 13-KODE, and
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Figure 2: Changes in metabolite levels between Ctrl and CIA mice. Individual metabolite levels for the two groups are illustrated using box-
plots with the whisker drawn, after logarithmic transformation for normalization. Boxplot colored: white box: metabolites in Ctrl group; grey
box: metabolites in CIA group. The metabolites which differed significantly based on Student’s 𝑡-test (𝑝 < 0.05) are marked with “∗”.
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12,13-EpOME). The top ten of them are also detected in
univariate 𝑡-test results, which confirmed the importance of
these oxylipins.
Given that the oxylipins 13,14-dihydro-PGF
2𝛼
and 12-
HETE have been implicated in inflammatory regulation in
disease and also given that they showed a meaningful VIP
score close to 1 (0.96, 0.95, resp.) with increasing trend in the
CIA group, changes in these metabolites can provide insight
in the biological interpretation for CIA and are included
in further biological interpretation. The detailed pieces of
information of 𝑝 value from Student’s 𝑡-test, VIP scores
from PLS-DA, and their direction of regulation are shown in
Table 1.
3.2. Physiological Pathways of Altered Oxylipins. We grouped
the detected oxylipins by their metabolic pathways in order
to illustrate their biological roles in Figure 3. Color is used
to indicate the up/downregulation (marked in yellow/blue
boxes) in the CIA group.
Among these colored 16 metabolites, all the 9 downreg-
ulated oxylipins (9,10-DiHOME, 9-KODE, 12,13-DiHOME,
9,12,13-TriHOME, 9,10,13-TriHOME, 9,10-EpOME, 9-HODE,
13-KODE, and 12,13-EpOME) are derived via the LA group;
3 upregulated oxylipins (8-HETE, 13,14-dihydro-PGF
2𝛼
, and
12-HETE) are derived from AA; 3 upregulated oxylipins
(14-HDoHE, 13-HDoHE, and 10-HDoHE) are derived from
DHA; and 1 upregulated oxylipin (12S-HEPE) is produced
from EPA.
4. Discussion
Inflammation is a self-limiting innate mechanism under
complex regulation with the purpose to recruit leukocytes
and plasma proteins, trafficking these to the site of infection
or tissue damage, supporting a robust adaptive immune
response and subsequent resolution [40]. RA is the conse-
quence of a systemic autoimmune activation/response within
the synovial fluid in the joint triggering a dysregulated
chronic inflammatory response, of which the exact underly-
ing pathogenic mechanisms still remain largely unclear. RA
is characterized with a strong inflamed cytokine phenotype
with elevated levels of IL-1𝛽, IL-6, and TNF𝛼 as well as
increased levels of ROS [18, 41, 42], seen in Figure 4(a).
Perturbations related to TNF𝛼 activation of the NF-𝜅B
pathway inhibiting apoptosis in activated antigen-presenting
cells including neutrophils,macrophages, fibroblast-like cells,
and B-cells form the general accepted pathological basis
of RA [9, 10, 43, 44]. Hence we applied a comprehensive
oxylipin metabolomics platform to the plasma of DBA/1J
mice induced by a coadministration of type II collagen
with lipopolysaccharide, to elucidate the role of these potent
inflammatory mediators in RA.
We detected an increased proinflammatory oxylipin
response, which can be attributed to the activation of NF-𝜅B
and increased ROS (Figure 4(b)). NF-𝜅B is the transcription
factor for COX-II, and its activation during RA [45, 46] can
explain the increased levels of theCOXderived prostaglandin
F
2𝛼
measured via its downstream product 13,14-dihydro-
PGF
2𝛼
in CIAmice [47, 48]. Several hydroxyl-fatty acids were
also implicated as role players in the chronic inflammatory
phenotype of RA. Due to two possible de novo synthesis
routes for hydroxyl-fatty acids, it implicates increased LOX
activity concurrently with elevated oxidative stress within
CIA mice [24–27]. Increased 12-LOX signaling mediators
included 8-HETE and 12-HETE supporting a proinflamma-
torymilieu [49, 50]. In an oral tolerance test in CIA rats, Ding
et al. [51] measured elevated levels of EPA-derived 18-HEPE,
while we detected increased level of a similar metabolite 12-
HEPE. Overexpression of 12-LOX in RA has been published
by Liagre and Kronke [52, 53], which can further mediate
the activation of NF-𝜅B [54–56], indicating the chronic
nature of RA. However, 8-HETE, 12-HETE, and 12-HEPE
together with the docosahexaenoic acid derived HDOHEs
also provide a readout for ROS induced biologically active
lipid peroxidation products [24–27]. Oxidative stress leading
to increased free radicals as well as ROS levels has been
reported in RA by Ozkan et al. [18], supporting this finding.
Alongside the increased pro-inflammatory oxylipins, we
also identified significantly decreased LA derived oxylipins
in CIA mice plasma. The decreased LA cytochrome P450
products (EpOMEs, DiHOMEs) and LA LOX products
(TriHOMEs) implicate a fatty acid precursor perturbation
and/or a possible oxylipin enzymatic impairment in RA. AA
is the ELOVL mediated elongation product of LA, and the
detected increasing trend in AA derived oxylipins indicate
sufficient CYP and LOX activity to rule out enzyme activity
as the cause of the LA oxylipin reductions. In addition, these
LA derived oxylipins as well as the decreased HODEs and
KODEs are ligands for nuclear hormone receptor peroxisome
proliferator-activated receptor-gamma (PPAR-𝛾) activation
[57–63], shown in Figure 4(c). PPAR-𝛾 are anti-inflammatory
regulators of immune cells and can inhibit the activation of
NF-𝜅B [44, 46, 61, 62, 64–70]. Therefore, the decreased LA-
derived oxylipins and PPAR-𝛾 ligands indicate a perturbation
in mechanisms related to the resolution of inflammation,
unable to inhibit NF-𝜅B activation and its downstream
inhibition of apoptosis.
As discussed above, our detected oxylipins indicate
insufficient PPAR-𝛾 ligands, as well as mechanisms leading
to the activation of NF-𝜅B, supporting and enhancing our
understanding of the inhibition of apoptosis in CIA mice.
Apoptosis plays an important role leading to the phago-
cytic clearances of damage cells stifling the development of
chronic inflammation and autoimmunity [71].The inhibition
of apoptosis prevents the silencing of activated leukocytes,
dysregulating clearance mechanisms contributing to chronic
autoimmune inflammation in RA [72].
5. Conclusion
Using our comprehensive oxylipin method we were able to
show that the CIA mice had an arachidonic acid dependent
increased proinflammatory profile, with increased levels of
oxidative stress. Several studies have been published advo-
cating anti-inflammatory diets (the restriction of AA in the
diet), leading to therapeutic benefits and ameliorating RA
[73]. We also detected a significant decrease in potent anti-
inflammatory oxylipins derived from linoleic acid capable



























































Figure 3: Overview of regulations of oxylipins in CIAmice compared with Ctrl, including metabolic pathways. Metabolites detected in mice
plasma are grouped by metabolic pathways. Important metabolites which contribute most to group clustering based on PLS-DA are colored:
yellow box: upregulated in the CIA group; blue box: downregulated in the CIA group.
of signaling via PPAR-𝛾 to inhibit the activation of NF-𝜅B,
namely, the molecular basis for RA. Interestingly, PPAR-
𝛾 has been identified and reported as a therapeutic agent
for arthritis [74]. The reduced levels of linoleic acid derived
oxylipins implicated fatty acid precursor pools, shedding light
on the unexplored routes of fatty acid elongation pathways in
the pathogenicity of RA, andneed furtherwork.As additional
metabolites have been reported to play a role in RA, a systems
biology approach would complement the study of systematic




CIA: Collagen induced arthritis
CII: Collagen type II
COX: Cyclooxygenase
CYP 450: Cytochrome P450 epoxygenases
DGLA: Dihomo-𝛾-linolenic acid
DHA: Docosahexaenoic acid
















































Figure 4: A systematic autoimmune activation in RA. Appearance of proinflammatory cytokines (IL-1𝛽 and IL-6, TNF𝛼) as well as the
appearance of ROS inRA.The cytokines normally induce the apoptosis via the caspase pathway but also inhibit apoptosis through degradation
I𝜅B activating nuclear factor-𝜅B (NF-𝜅B), which consequently translocate to the nucleus upregulating the antiapoptotic genes (BcL2 and
BcL-xL). The activated NF-𝜅B then can also further enhance the production of proinflammatory cytokines and chemokines as well as COX-
II enzyme. (b) Upregulated oxylipin response. During RA increased levels of AA derived prostaglandins and HETEs are detected. 8- and
12-HETE are able to activate NF-𝜅B exasperating RA. Due to increased levels of ROS, DHA derived peroxidation products are also found.
(c) Dysregulated anti-inflammatory response. LA derived oxylipins including HODEs, KODEs, TriHOMEs, DiHOMEs, and EpOMEs are
ligands of peroxisome proliferator-activated receptor- (PPAR-) 𝛾. Due to decreased levels of these anti-inflammatory oxylipins, the ability of
PPAR-𝛾 to inhibit the activation of NF-𝜅B and indirectly affect apoptosis is diminished.
DiHETrE: Dihydroxyeicosatrienoic acid




















NF-𝜅B: Nuclear factor-kappa B
PG: Prostaglandin
PPAR: Peroxisome proliferator-activated receptor
RA: Rheumatoid arthritis
ROS: Reactive oxygen species
sEH: Soluble epoxide hydrolase
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